Price T Rowe Associates Inc Amicus Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,341,921 shares of FOLD stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,341,921
Previous 1,390,047
3.46%
Holding current value
$12.7 Million
Previous $13.8 Million
3.93%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FOLD
# of Institutions
313Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$274 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$267 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$232 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$228 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$220 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.66B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...